Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Tumor-Agnostic 1NET 1Head & Neck 1

Conditions

Neuroendocrine Tumors 12Gastro-enteropancreatic neuroendocrine tumor 4Carcinoid Tumor 3Neoplasms 2Carcinoma, Islet Cell 2Adenoma, Islet Cell 2Vipoma 1Somatostatinoma 1Serotonin Syndrome 1Pancreatic Neuroendocrine Tumor G2 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Hepatocellular 1Carcinoma 1Acromegaly 1

Interventions

Everolimus 3tislelizumab 1surufatinib 1romidepsin 1regorafenib 1pembrolizumab 1pasireotide 1lutetium Lu 177 dotatate 1folfirinox 1fludarabine phosphate 1epothilone B 1cixutumumab 1Surgical Procedures, Operative 1Sunitinib 1Specimen Handling 1Radiosurgery 1Octreotide 1Magnetic Resonance Spectroscopy 1Liver Transplantation 1Lactones 1LY2584702 1Interleukin-13 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Erlotinib Hydrochloride 1Embolization, Therapeutic 1Doxorubicin 1Depsipeptides 1Cytokines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Octreotide × NET × Clear all
NCT00781911 2019-09-20

A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer

Eli Lilly and Company

Phase 2 Completed
43 enrolled 12 charts
EndocrineNET

Carcinoid Tumor, Carcinoma, Neoplasm Metastasis, Carcinoma, Islet Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡